Social Responsiveness as a Mediator in Adapted Cognitive Behavioral Therapy for Autistic Youth with Maladaptive and Interfering Anxiety.

J Autism Dev DisordMay 7, 2025 (epub)
Clinical ResearchPsychiatryPediatricsOpen access

Jeffrey J Wood, Eric A Storch, Katherine Sung et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary mediation analysis of a multisite randomized clinical trial examined whether improved social responsiveness helped explain outcomes with adapted cognitive behavioral therapy (BIACA) in autistic youth aged 7–13 with maladaptive and interfering anxiety (N = 167). BIACA was compared with standard-of-practice CBT and treatment as usual. The analysis found a statistically significant indirect effect: adapted CBT’s effect on anxiety was mediated by social responsiveness. Youth assigned to adapted CBT also had better overall mental health at posttreatment than those in the other conditions, with this effect likewise mediated by improved social responsiveness.

Key findings

  • The effect of adapted CBT on anxiety was mediated by social responsiveness, with a statistically significant indirect effect.
  • Adapted-CBT participants had better overall mental health at posttreatment than participants in the other conditions.
  • Improved social responsiveness also mediated the adapted CBT effect on overall mental health.

Why it matters

The findings suggest that social responsiveness may be one pathway through which CBT adapted to autistic youths’ social needs relates to anxiety and broader mental health outcomes. This highlights the potential relevance of social supports within CBT, including for navigating stressful situations such as group activities, while the mediation analysis does not establish that social responsiveness alone caused the benefits.

What to keep in mind

This was a secondary mediation analysis of a randomized trial; the abstract does not report the size of the indirect effects or establish that changes in social responsiveness caused the outcomes.

Source

Published in J Autism Dev Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.